Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Nov 4, 2025
Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025
Initiated KT-621 BROADEN2 Phase 2b trial in AD
Read more at globenewswire.com
